Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Amphibian ribonuclease A; Onconase; P-30 protein - Alfacell; P-30 ribonuclease

Latest Information Update: 11 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alfacell Corporation
  • Developer Alfacell Corporation; Tamir Biotechnology
  • Class Antineoplastics; Ribonucleases
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Protein synthesis inhibitors; Ribonuclease stimulants; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Ebola virus infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Genital warts; Human papillomavirus infections
  • Preclinical Ebola virus infections; Zika virus infection
  • Discontinued Acute myeloid leukaemia; Brain cancer; Chronic lymphocytic leukaemia; HIV infections; Mesothelioma; Neuroblastoma; Pancreatic cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 08 Aug 2017 Ranpirnase receives Orphan Drug status for Ebola virus infections in USA
  • 08 Mar 2017 Efficacy data from a phase I/II trial in Genital warts and Human papillomavirus infections released by Tamir Biotechnology
  • 01 Sep 2016 Tamir Biotechnology completes a phase I/II trial in Genital warts and Human papillomavirus infections in Bolivia (NCT02535104)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top